"Ligand Pharmaceuticals Raises $100 Million for Acquisitions and Drug Development"

Ligand Pharmaceuticals Acquires Apeiron Biologics for $100M

Ligand Pharmaceuticals (Linkedin) has made a strategic move by acquiring Apeiron Biologics for $100 million. This acquisition grants Ligand the royalty rights to QARZIBA®, a highly sought-after oncology drug available in over 35 countries.

Acquisition Amount: $100 million

Industry: Biotechnology Research

Employee Count: 11-50

CEO: Todd Davis (CEO Linkedin)

What Ligand Pharmaceuticals needs to buy: Ligand Pharmaceuticals is seeking partnerships with biopharmaceutical companies engaged in mid- to late-stage drug development. They are also interested in licensing opportunities for their technology and expanding their market reach through new collaborations in the biopharmaceutical industry. Companies specializing in drug development, technology licensing, and market expansion strategies are ideal partners for Ligand Pharmaceuticals.